Nureca Ltd Stock Price Today (NSE: NURECA)
Fundamental Score
Nureca Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Nureca Ltd share price today is ₹239.05, up +0.27% on NSE/BSE as of 17 June 2026. Nureca Ltd (NURECA) is a Small-cap company in the Medical Equipment & Supplies sector with a market capitalisation of ₹292.61 (Cr). The 52-week high for NURECA share price is ₹343.00 and the 52-week low is ₹204.00. At a P/E ratio of 71.19x, NURECA is currently trading above its industry average P/E of 47.87x. The company has a Return on Equity (ROE) of -1.12% and a debt-to-equity ratio of 0.03.
Nureca Ltd Share Price Chart — NSE/BSE Historical Performance
Nureca Ltd share price chart: 2.39% return over the past month. 52-week high ₹343.00, 52-week low ₹204.00.
Nureca Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹236.00 | ₹244.65 | ₹235.10 | ₹237.25 | 21.16K (Cr) | |
| ₹232.30 | ₹249.60 | ₹232.30 | ₹240.05 | 1.25L (Cr) | |
| ₹274.95 | ₹287.05 | ₹272.40 | ₹281.45 | 17.25K (Cr) | |
| ₹274.55 | ₹276.35 | ₹270.85 | ₹272.15 | 5.48K (Cr) | |
| ₹273.00 | ₹277.70 | ₹273.00 | ₹274.35 | 5.31K (Cr) | |
| ₹279.65 | ₹279.65 | ₹270.55 | ₹273.35 | 5.01K (Cr) | |
| ₹272.30 | ₹274.00 | ₹270.65 | ₹272.20 | 4.15K (Cr) | |
| ₹271.40 | ₹279.45 | ₹271.20 | ₹271.80 | 7.73K (Cr) | |
| ₹274.50 | ₹276.85 | ₹270.30 | ₹272.65 | 4.17K (Cr) | |
| ₹272.90 | ₹279.90 | ₹271.55 | ₹276.45 | 5.33K (Cr) |
Nureca Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹232.30 | ₹249.60 | ₹232.30 | ₹237.25 | +2.13% | |
| ₹265.45 | ₹300.00 | ₹258.95 | ₹281.45 | +6.03% | |
| ₹208.05 | ₹274.90 | ₹208.05 | ₹266.51 | +28.10% | |
| ₹289.20 | ₹295.15 | ₹204.00 | ₹206.75 | -28.51% | |
| ₹275.00 | ₹307.00 | ₹265.15 | ₹295.20 | +7.35% | |
| ₹316.00 | ₹334.50 | ₹270.00 | ₹277.85 | -12.07% | |
| ₹294.00 | ₹315.00 | ₹270.50 | ₹307.95 | +4.74% | |
| ₹260.00 | ₹293.00 | ₹247.00 | ₹289.60 | +11.38% | |
| ₹229.00 | ₹343.00 | ₹226.84 | ₹261.50 | +14.19% | |
| ₹246.00 | ₹278.40 | ₹226.00 | ₹230.48 | -6.31% | |
| ₹250.00 | ₹253.49 | ₹230.20 | ₹240.11 | -3.96% | |
| ₹284.80 | ₹314.60 | ₹235.10 | ₹249.05 | -12.55% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Momentum-driven microcap with stretched valuation and governance concerns; avoid.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Nureca's stock experienced notable volatility. On April 1, 2026, it locked at a 10% upper circuit, closing at Buyers queued up, and sellers were absent, indicating strong buying interest. Volume on that day was 0.09825 lakh shares, with a turnover of Delivery volume surged 81.11% against the 5-day average, suggesting genuine buying conviction. However, Markets Mojo downgraded Nureca to a Strong Sell on April 8, 2026, citing bearish technicals and expensive valuation.
CORE STORY (THE REAL GAME)
- Upper circuit fueled short-term bullishness
- Q3 FY26 results showed revenue and profit growth
- Promoter buying adds confidence
- Sustained revenue growth in subsequent quarters
- New product launches in the home healthcare segment
- Positive regulatory changes for the medical device industry
- Stretched valuation (P/E of 71.19x vs. industry P/E of 47.87x)
- Negative ROE and ROCE
- Microcap liquidity risk
- Warning letters from BSE and NSE for non-compliance
Promoter increased stake by 0.64%. FII and DII holdings are negligible.
India's medical devices sector is projected to reach US$50 billion by 2030, but Nureca's ability to capture this growth is questionable.
Free Cash Flow 5Y: ₹14.2 Cr. Profit converting to cash is questionable.
Short-term momentum may continue, but long-term sustainability is doubtful. Expect a correction as growth normalizes.
Primary Thesis Risk
Unsustainable growth expectations leading to valuation collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Nureca Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Nureca Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NURECA across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (856.25%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (21.00%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (64.97%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-1.12%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.90%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 71.19x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (1.98% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Nureca Ltd vs Medical Equipment & Supplies Peers
Peer Comparison - Medical Equipment & Supplies
Compare Nureca Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Nureca LtdNureca Ltd...Selected✓ NURECA • 543264 | 36/100 | ₹239.05₹239 | ₹292.61₹292.61 | 71.19Average 71.2 Average | -1.12%Poor -1.12% Poor | -0.90%Poor -0.90% Poor | 0.03Excellent 0.0 Excellent | — — | 1.98%Average 1.98% Average | 0.00% |
Poly Medicure LtdPoly Medicure L... POLYMED • 531768 | 60.7/100 | ₹1330.30₹1330 | ₹19506.20₹19506.20 | 53.89Average 53.9 Average | 15.77%Good 15.77% Good | 20.08%Excellent 20.08% Excellent | 0.08Excellent 0.1 Excellent | 28.38%Excellent 28.38% Excellent | 19.44%Excellent 19.44% Excellent | 0.18% |
Fischer Medical Ventures LtdFischer Medical... FISCHER • 524743 | 31.7/100 | ₹37.46₹37 | ₹3162.93₹3162.93 | 157.52Average 157.5 Average | 0.70%Poor 0.70% Poor | 1.08%Poor 1.08% Poor | 0.08Excellent 0.1 Excellent | — — | — — | 0.01% |
Laxmi Dental LtdLaxmi Dental Lt... LAXMIDENTL • 544339 | 68.7/100 | ₹243.13₹243 | ₹1488.44₹1488.44 | 57.78Average 57.8 Average | 21.88%Excellent 21.88% Excellent | 19.20%Good 19.20% Good | 0.04Excellent 0.0 Excellent | 57.51%Excellent 57.51% Excellent | 9.81%Good 9.81% Good | 0.00% |
OSEL DEVICES LIMITEDOSEL DEVICES LI... OSELDEVICE • | 42.1/100 | ₹496.70₹497 | ₹1363.11₹1363.11 | 50.06Average 50.1 Average | 30.08%Excellent 30.08% Excellent | 31.14%Excellent 31.14% Excellent | 0.56Good 0.6 Good | — — | — — | 0.00% |
Tarsons Products LtdTarsons Product... TARSONS • 543399 | 13.8/100 | ₹214.98₹215 | ₹1224.98₹1224.98 | 59.58Average 59.6 Average | 4.75%Poor 4.75% Poor | 6.91%Poor 6.91% Poor | 0.63Good 0.6 Good | — — | — — | 0.00% |
60.3/100 | ₹173.00₹173 | ₹633.93₹633.93 | 25.77Average 25.8 Average | 36.78%Excellent 36.78% Excellent | 31.12%Excellent 31.12% Excellent | 0.53Good 0.5 Good | 90.06%Excellent 90.06% Excellent | 61.82%Excellent 61.82% Excellent | 0.00% | |
Prevest Denpro LtdPrevest Denpro ... PREVEST • 543363 | 68.5/100 | ₹408.00₹408 | ₹521.17₹521.17 | 26.18Average 26.2 Average | 18.74%Good 18.74% Good | 25.25%Excellent 25.25% Excellent | 0.00Excellent 0.0 Excellent | 29.49%Excellent 29.49% Excellent | 22.80%Excellent 22.80% Excellent | 0.23% |
HSIL LimitedHSIL Limited... HSIL • 543916 | 61.2/100 | ₹413.00₹413 | ₹354.57₹354.57 | 34.23Average 34.2 Average | 13.58%Average 13.58% Average | 16.35%Good 16.35% Good | 0.43Excellent 0.4 Excellent | 74.11%Excellent 74.11% Excellent | 13.69%Good 13.69% Good | 0.00% |
47.7/100 | ₹187.00₹187 | ₹294.37₹294.37 | 32.71Average 32.7 Average | 13.56%Average 13.56% Average | 18.45%Good 18.45% Good | 0.01Excellent 0.0 Excellent | — — | — — | 0.00% | |
29.6/100 | ₹84.50₹85 | ₹189.41₹189.41 | 15.39Average 15.4 Average | 14.36%Average 14.36% Average | 16.60%Good 16.60% Good | 0.55Good 0.6 Good | — — | — — | 0.51% | |
Top Medical Equipment & Supplies Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Poly Medicure Ltd share price19506.20 Cr
- Fischer Medical Ventures Ltd share price3162.93 Cr
- Laxmi Dental Ltd share price1488.44 Cr
- OSEL DEVICES LIMITED share price1363.11 Cr
- Tarsons Products Ltd share price1224.98 Cr
Nureca Ltd PE Ratio History
Historical price-to-earnings ratio for NURECA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.85 | ₹307.95 | 362.3x |
| FY 2022 | ₹44.96 | ₹498.15 | 11.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Nureca Ltd Dividend History
Annual cash dividends paid by NURECA — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹4.99 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Nureca Ltd Quarterly Performance
Latest quarterly metrics for NURECA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
21.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
856.25%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
1.98%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Nureca Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NURECA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Nureca Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Nureca Ltd (NURECA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Nureca Ltd
About NURECA (Nureca Ltd)
Nureca Ltd is a dynamic Indian enterprise focused on empowering individuals to proactively manage their health and well-being from the comfort of their homes. They curate and distr...ibute a comprehensive range of medical devices and lifestyle products designed to address both acute and chronic conditions. The company's portfolio encompasses essential diagnostic tools, enabling users to monitor vital signs and track key health indicators. Beyond diagnostics, Nureca offers solutions for pain management, rehabilitation, and overall physical wellness. Their dedication to providing high-quality, user-friendly products reflects a commitment to making healthcare accessible and convenient for all. Nureca's offerings span a wide spectrum of needs, ranging from devices that assist in managing respiratory ailments to innovative gadgets that promote fitness and relaxation. For individuals grappling with chronic conditions, they provide essential tools like blood glucose monitors for diabetes management, and blood pressure monitors for hypertension control. Simultaneously, Nureca caters to the growing interest in preventive healthcare and wellness by offering products such as posture correctors and massagers that aid in musculoskeletal health. This holistic approach underscores their vision of creating a healthier and more informed society. The company strategically positions itself at the intersection of healthcare and technology, integrating connected features into select products to enhance user experience and data tracking. By seamlessly blending traditional medical devices with modern connectivity, Nureca strives to provide consumers with a comprehensive and integrated approach to healthcare management. Their dedication to product quality, coupled with their commitment to innovation and customer satisfaction, solidifies Nureca's position as a leader in the rapidly evolving home healthcare market in India.
Company Details
Key Leadership
Corporate Events
NURECA Share Price: Frequently Asked Questions
What is the current share price of Nureca Ltd?
Nureca Ltd (NURECA) trades at ₹239.05 on NSE and BSE. Market cap ₹292.61 (Cr). Educational data only.
What is the P/E ratio of Nureca Ltd?
Nureca Ltd has a P/E of 71.19x vs industry average 47.87x.
What is the Bull Run score for Nureca Ltd?
Nureca Ltd has a Bull Run score of 36/100 based on 25+ financial parameters.
Does Nureca Ltd pay dividends?
Nureca Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Nureca Ltd?
Nureca Ltd has ROE of -1.12%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Nureca Ltd?
Nureca Ltd has debt-to-equity of 0.03.
Is Nureca Ltd a good investment?
Bull Run gives Nureca Ltd a score of 36/100. This is not investment advice — consult a SEBI-registered advisor.